Legend Biotech is a global biotechnology company dedicated to treating and, one day, curing life-threatening diseases. Headquartered in Bridgewater, New Jersey, we are advancing the next generation of cell therapy through a portfolio of innovative technologies, including autologous, allogeneic, and in vivo cell therapy approaches. Our research spans chimeric antigen receptor T-cell (CAR-T), T-cell receptor (TCR-T), natural killer (NK) cell-based therapies, and other emerging platforms designed to transform the treatment of serious diseases. From our global network of research and development sites, we are committed to discovering and developing safe, effective, and cutting-edge therapies for patients worldwide.

Legend Biotech entered into a global collaboration agreement with Johnson & Johnson to jointly develop and commercialize CARVYKTI® (ciltacabtagene autoleucel; cilta-cel). Through this strategic partnership, we combine complementary expertise and capabilities to advance innovative immunotherapies for patients living with multiple myeloma.

Legend Biotech is seeking a Sr. Manager Network Finance & Strategy as part of the Finance team based in Bridgewater, NJ.

Role Overview

The Senior Manager, Network Finance & Strategy is a strategic finance leader responsible for financial planning, performance management, and decision support across Legend Biotech’s global manufacturing and supply network. The role provides an integrated financial perspective across manufacturing sites, external manufacturing partners, supply-chain functions, and portfolio programs.

Reporting to the Director, Supply Chain Finance, this position leads the financial evaluation of manufacturing network strategies, major investments, capacity decisions, automation initiatives, and gross-margin opportunities. The Senior Manager partners with Manufacturing, Supply Chain, Quality, MSAT, Engineering, Procurement, and Finance leadership to translate operational strategies into clear financial implications and recommendations.

The position also leads Network FP&A and supports the continued expansion of Supply Chain Finance beyond CARVYKTI to Legend’s broader pipeline. The role oversees consolidated planning and performance management while developing the financial frameworks, analytics, and team capabilities required to support future growth and commercialization.

Key Responsibilities

Network Strategy and Decision Support

Lead the financial evaluation of manufacturing network strategies, including capacity expansion, volume allocation, product transfers, sourcing alternatives, and network configuration decisions.
Develop scenario analyses that assess COGM, gross margin, capital requirements, cash flow, operational risk, and long-term financial implications.
Serve as the primary Finance partner for strategic network-capacity planning and provide clear recommendations to support leadership decisions.

Strategic Investments and Business Cases

Lead financial evaluations for automation, capacity expansion, technology investments, new facilities, and other manufacturing and supply-chain initiatives.
Develop robust business cases incorporating NPV, ROI, payback, cash flow, depreciation, COGM, gross-margin impact, and sensitivity analysis.
Lead the financial assessment of make-versus-buy, internal-versus-external manufacturing, CMO sourcing, and manufacturing-footprint decisions.

Gross Margin and Network Competitiveness

Lead network-level financial analysis supporting long-term gross-margin expansion, manufacturing productivity, and cost competitiveness.
Partner with Site Finance and operational leaders to identify, evaluate, prioritize, and track cross-site productivity and cost-improvement opportunities.
Develop financial roadmaps connecting volume growth, operational improvements, automation, network optimization, and capital investment to long-term margin objectives.

Portfolio Manufacturing Finance

Provide strategic Finance support for manufacturing and supply-chain decisions associated with pipeline products and future commercialization.
Evaluate product economics, financial flows, manufacturing locations, capacity requirements, sourcing strategies, and investment timing for new programs.
Integrate pipeline assumptions into manufacturing-network strategy, capital planning, and the long-range financial outlook.

Network FP&A Leadership

Lead consolidated budgeting, forecasting, long-range planning, performance management, and reporting across the manufacturing and supply network.
Oversee the Manager, Network FP&A in coordinating site submissions, maintaining planning models, consolidating results, and preparing management reporting.
Challenge financial and operational assumptions and synthesize results into clear insights, risks, opportunities, and recommendations for leadership.

Executive Business Partnership

Serve as a trusted Finance advisor to Manufacturing, Supply Chain, Quality, MSAT, Engineering, Procurement, and Finance leadership.
Represent Supply Chain Finance in relevant operating, planning, governance, and leadership forums and act as a delegate to the Director, Supply Chain Finance when appropriate.
Translate complex operational and financial information into concise, decision-oriented recommendations for senior leaders.

Finance Transformation and Analytics

Establish priorities for Network Finance transformation, including planning models, dashboards, reporting automation, advanced analytics, and scalable data solutions.
Partner with Finance, IT, and data teams to improve the availability, quality, governance, and use of manufacturing and supply-chain data.
Drive standardization and automation to reduce manual processes and improve the speed, reliability, and decision usefulness of financial insights.

Team Leadership and Development

Lead, coach, and develop the Network FP&A team, establishing clear objectives, responsibilities, and performance expectations.
Build team capabilities in manufacturing finance, strategic modeling, analytics, executive communication, and business partnership.
Foster a culture of accountability, collaboration, continuous improvement, and high-quality financial analysis.
The Senior Manager, Network Finance & Strategy works closely with the Director, Supply Chain Finance; Manager, Network FP&A Site Finance leaders; Global Supply Chain Accounting; Corporate FP&A Commercial Finance; Manufacturing; Supply Chain; Quality; MSAT; Engineering; Procurement; Clinical Supply; Corporate Accounting; Tax; IT; and data and analytics teams.

Requirements

Bachelor’s degree in Finance, Accounting, Business Administration, Economics, or a related field required.
Advanced degree and/or relevant professional accounting/finance qualification preferred.
Significant progressive experience in FP&A, manufacturing finance, supply-chain finance, strategic finance, or a related discipline.
Demonstrated experience leading complex financial planning, strategic modeling, business-case development, and executive decision support.
Experience supporting manufacturing-network decisions, capital investments, automation, capacity expansion, or external-manufacturing strategies preferred.
Experience within pharmaceutical, biotechnology, cell therapy, medical technology, or another regulated manufacturing environment preferred.
Demonstrated experience leading employees and influencing senior stakeholders across functions and geographies.
Strong knowledge of manufacturing economics, COGM, gross margin, capacity planning, inventory, productivity, and capital investment.
Advanced financial modeling and business-case development capabilities.
Strong FP&A, forecasting, long-range planning, performance-management, and analytical skills.
Ability to translate complex analysis into clear executive recommendations.
Strong business-partnering and influencing skills across functions, sites, and leadership levels.
Demonstrated ability to lead teams, navigate ambiguity, and manage multiple strategic priorities.
Strong systems orientation and commitment to data quality, automation, and scalable analytics.

#Li-LB1

#Li-Hybrid

The base pay range below is what Legend Biotech USA Inc. reasonably expects to offer at the time of posting. Actual compensation may vary based on experience, skills, qualifications, and geographic location. The company reserves the right to modify this range as needed and in accordance with applicable laws.

Other Types of Pay: Performance-based bonus and/or equity is available to employees in eligible roles.

Benefits and Paid Time Off: Medical, dental, and vision insurance as well as a 401(k) retirement plan with a company match that vests fully on day one. We offer eight (8) weeks of paid parental leave after just three (3) months of employment, and a paid time off policy that includes vacation time, personal time, sick time, floating holidays, and eleven (11) company holidays. Additional voluntary benefits include flexible spending and health savings accounts, life and AD&D insurance, short- and long-term disability coverage, legal assistance, and supplemental plans such as pet, critical illness, accident, and hospital indemnity insurance. We also provide voluntary commuter benefits, family planning and care resources, well-being initiatives, and peer-to-peer recognition programs; demonstrating our ongoing commitment to building a culture where our people feel empowered, supported, and inspired to do their best work.

Pay Range (Base Pay):

$127,313—$167,099 USD

Please note: These benefits are offered exclusively to permanent full-time employees. Contractors are not eligible for benefits through Legend Biotech.

Work Authorization & Employment Eligibility

Applicants must be authorized to work in the United States. As part of our commitment to maintaining a lawful workforce and ensuring compliance with federal employment regulations, we participate in the E-Verify program. If you are selected for employment, you will be required to complete the Form I-9 process, and your employment eligibility will be verified through E-Verify in accordance with applicable federal law. We are committed to providing a fair, transparent, and welcoming hiring experience for all candidates.

EEO Statement

It is the policy of Legend Biotech to provide equal employment opportunities without regard to actual or perceived race, color, creed, religion, national origin, ancestry, citizenship status, age, sex or gender (including pregnancy, childbirth, related medical conditions and lactation), gender identity or gender expression (including transgender status), sexual orientation, marital status, military service and veteran status, disability, genetic information, or any other protected characteristic under applicable federal, state or local laws or ordinances.

Employment is at-will and may be terminated at any time with or without cause or notice by the employee or the company.

For information related to our privacy notice, please review: Legend Biotech Privacy Notice.

Pay Range (Base Pay): 127313 - 167099 USD

About the company

Legend Biotech develops and commercializes cell therapies for serious diseases, including hematologic cancers and solid tumors, with a focus on personalized medicine. Its therapies, like CAR-T treatments, work by collecting a patient’s cells, engineering them to target cancer cells, expanding them, and reinfusing them into the patient. The company differentiates itself by using multiple technology platforms (technology-agnostic) and pursuing a broad pipeline, including exclusive global licenses for CAR-T therapies. Its goal is to bring effective, personalized cell therapies to market, improve outcomes for hard-to-treat cancers, and maintain transparent communication with investors while expanding globally.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bridgewater Township, New Jersey

Founded

2014

Get referred to Legend Biotech

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue rose 51.9% to $387.5 million, beating estimates decisively.
CARVYKTI sales reached $657 million, up 50%, with 348 sites across 19 markets.
Legend posted first company-wide quarterly profit in Q2 2026, proving operating leverage.

What critics are saying

CARVYKTI supplies most revenue; any slowdown hits Legend's entire valuation immediately.
2seventy bio's January 2026 UPC lawsuit threatens European CARVYKTI sales and damages.
Bispecifics from J&J, Bristol Myers Squibb, and others compress multiple myeloma share by 2027.

What makes Legend Biotech unique

CARVYKTI, co-developed with Johnson & Johnson, drives Legend's global commercial moat.
Legend's Raritan expansion supports treatment for 10,000 patients annually, scaling manufacturing.
Ingrid Zhang joined September 15, 2026, bringing Novartis, AstraZeneca, Pfizer commercial depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Paid Sick Leave
Paid Holidays
Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Yahoo Finance

Sep 15th, 2026

Legend Biotech names Novartis executive Ingrid Zhang as CEO

Legend Biotech is expected to name Ingrid Zhang as chief executive, with an announcement anticipated as early as Tuesday morning, according to people familiar with the matter. The move is expected to be effective immediately. Zhang has served as Novartis's international chief commercial officer since 2024. She previously held leadership roles at AstraZeneca and Pfizer, and was a McKinsey consultant. Legend launched a search for a new CEO after Ying Huang resigned on 24 July, sending shares tumbling more than 10%. The company's CAR-T therapy Carvykti brought in $1.9 billion in sales last year and more than $1 billion in the first half of this year.

Associated Press

Sep 15th, 2026

Legend Biotech appoints Ingrid Zhang as chief executive officer

Legend Biotech has appointed Ingrid Zhang as chief executive officer, effective 15 September 2026. Zhang succeeds Alan Bash, who served as interim chief executive officer since July 2026 and will return to his role as president of CARVYKTI. Zhang joins from Novartis International, where she most recently served as chief commercial officer. During her tenure at Novartis, she also led the company's China business and innovative medicines organisation. She previously held leadership positions at AstraZeneca, Pfizer, and McKinsey & Company. Legend Biotech is a cell therapy company with over 3,000 employees. The company develops CARVYKTI, a CAR-T cell therapy for relapsed or refractory multiple myeloma, in collaboration with Johnson & Johnson.

MarketBeat

Aug 12th, 2026

Legend Biotech (NASDAQ:LEGN) given new $58.00 price target at Royal Bank Of Canada.

Legend Biotech (NASDAQ:LEGN) given new $58.00 price target at Royal Bank Of Canada. August 12, 2026 Key points. * Royal Bank of Canada lowered Legend Biotech's price target to $58 from $59 while maintaining an "outperform" rating, implying 176.32% potential upside from the prior close. * Legend Biotech reported quarterly EPS of $0.09 versus the $0.07 consensus estimate, while revenue of $387.5 million exceeded expectations and increased 51.9% year over year. * Shares fell 3.8% to $20.99, despite generally favorable analyst coverage; eight analysts rate the stock a Buy, six a Hold and one a Sell, with an average target price of $52.57. * Five stocks to consider instead of Legend Biotech. Legend Biotech (NASDAQ:LEGN - Get Free Report) had its target price cut by analysts at Royal Bank Of Canada from $59.00 to $58.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Royal Bank Of Canada's price objective would indicate a potential upside of 176.32% from the company's previous close. LEGN has been the subject of several other research reports. HC Wainwright reiterated a "buy" rating and issued a $65.00 price target on shares of Legend Biotech in a report on Tuesday, July 28th. Weiss Ratings upgraded shares of Legend Biotech from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, July 30th. JPMorgan Chase & Co. started coverage on shares of Legend Biotech in a research report on Monday, July 13th. They issued a "neutral" rating and a $35.00 price objective on the stock. Barclays reduced their target price on shares of Legend Biotech from $80.00 to $78.00 and set an "overweight" rating for the company in a research note on Wednesday. Finally, Benchmark reiterated a "buy" rating on shares of Legend Biotech in a report on Tuesday, July 28th. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $52.57. Legend Biotech trading down 3.8%. Shares of NASDAQ:LEGN traded down $0.84 during trading on Wednesday, hitting $20.99. 222,918 shares of the company's stock traded hands, compared to its average volume of 2,499,674. Legend Biotech has a 52 week low of $16.24 and a 52 week high of $38.35. The company has a market cap of $3.90 billion, a price-to-earnings ratio of -31.07 and a beta of 0.37. The company has a 50-day moving average price of $26.68 and a 200-day moving average price of $23.15. Legend Biotech (NASDAQ:LEGN - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.02. The business had revenue of $387.50 million during the quarter, compared to analysts' expectations of $355.96 million. Legend Biotech had a negative return on equity of 24.92% and a negative net margin of 21.98%.Legend Biotech's revenue for the quarter was up 51.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.03 EPS. On average, analysts predict that Legend Biotech will post -0.01 earnings per share for the current fiscal year. Insiders place their bets. In other news, CEO Ying Huang sold 5,566 shares of the firm's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $14.78, for a total transaction of $82,265.48. Following the completion of the transaction, the chief executive officer directly owned 241,872 shares of the company's stock, valued at $3,574,868.16. This trade represents a 2.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.02% of the stock is currently owned by company insiders. Institutional trading of Legend Biotech. Institutional investors have recently made changes to their positions in the business. First Trust Advisors LP bought a new stake in Legend Biotech during the 2nd quarter worth about $411,000. Squarepoint Ops LLC grew its holdings in shares of Legend Biotech by 77.6% in the 2nd quarter. Squarepoint Ops LLC now owns 148,681 shares of the company's stock valued at $5,277,000 after acquiring an additional 64,956 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Legend Biotech by 16.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 84,081 shares of the company's stock valued at $2,984,000 after acquiring an additional 11,771 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Legend Biotech by 3.5% in the second quarter. Alliancebernstein L.P. now owns 1,560,596 shares of the company's stock valued at $55,386,000 after acquiring an additional 52,344 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Legend Biotech in the second quarter valued at about $15,790,000. Institutional investors own 70.89% of the company's stock. Here are the key news stories impacting Legend Biotech this week: * Positive Sentiment: Legend Biotech reported second-quarter EPS of $0.09, exceeding the $0.07 analyst consensus. Revenue reached $387.5 million, ahead of the $355.96 million estimate and up 51.9% year over year, providing evidence of continued commercial momentum. Legend Biotech earnings report * Positive Sentiment: Coverage highlighted adjusted EPS that was approximately double consensus expectations and the company's first quarter of company-wide profitability, strengthening the investment case for operating leverage as sales grow. Legend Biotech gains on earnings beat * Positive Sentiment: Analysts set a reported price target of $55.29 for Legend Biotech, substantially above the stock's recent trading level. The target signals considerable potential upside if Carvykti growth and the company's profitability trajectory continue. Analysts set Legend Biotech price target * Neutral Sentiment: Investor attention remains focused on Carvykti demand, manufacturing capacity and management's outlook, which will determine whether the latest revenue growth can be sustained. Legend Biotech Carvykti earnings preview * Neutral Sentiment: A report showing zero shares sold short and a zero-day short-interest ratio appears inconsistent with normal market data, limiting its usefulness as a signal for trading sentiment. Legend Biotech company profile. Legend Biotech NASDAQ: LEGN is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson. The company's lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)-directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Legend Biotech, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list. While Legend Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Yahoo Finance

Aug 11th, 2026

Legend Biotech shares rise 5% as Q2 earnings beat, CARVYKTI sales jump 50%

Legend Biotech shares rose 5.5% in pre-market trading after reporting second-quarter results that exceeded expectations. The pharmaceutical company posted adjusted earnings of $0.16 per share, more than double the $0.07 analyst consensus, whilst revenue reached $387.5M, ahead of the $362.81M estimate. CARVYKTI net trade sales hit approximately $657M during the quarter, representing 50% year-on-year growth. US sales increased 32%, whilst international sales jumped 128%. The therapy is now available through 348 sites across 19 markets. Legend Biotech swung to operating profit, recording operating income of $57.7M compared with a $21.9M loss in the same quarter last year. Net income reached $33.2M, reversing a $125.4M loss from the previous year.

Market Chameleon

Aug 11th, 2026

Legend Biotech achieves profitability and breakthroughs in cell therapy with Q2 2026 results.

Legend Biotech achieves profitability and breakthroughs in cell therapy with Q2 2026 results. 11 August 2026, 7:35 AM First-Ever quarterly profit and major pipeline progress highlight Q2. Legend Biotech's second quarter of 2026 marked a major inflection point: the company posted its first-ever quarterly profit, driven by a surge in global CARVYKTI(R) sales, expansion into new markets, and significant milestones in its innovative cell therapy pipeline. The financial and clinical progress underscores the company's momentum as it advances toward company-wide profitability and sector leadership. CARVYKTI(R) drives robust revenue Growth across global markets. Net trade sales of CARVYKTI(R) soared 50% versus Q2 2025 to $657 million, fueled by launches in new territories - including Ireland, Legend's 19th global market. U.S. net sales grew 32% year-over-year, with ex-U.S. markets notching a remarkable 128% increase. CARVYKTI(R) is now available at 348 global sites, reflecting an accelerating trajectory for patient access and commercial reach. | Region | Q2 2026 Net Sales ($M) | YOY Growth (%) | Global Sites | | U.S. 472.0 | 32 | 348 | | Rest of World | 185.0 | 128 | | Total | 657.0 | 50 | - | Pipeline shows clinical momentum: 100% ORR for LB2501 at high dose. Legend notched its first clinical proof-of-concept for LB2501, an innovative in vivo CD19/CD20 dual-targeting CAR-T therapy. At the higher dose level, 100% overall response rate (ORR) and 83.3% complete response (CR) were observed in relapsed/refractory B-cell non-Hodgkin lymphoma - without serious adverse events or dose-limiting toxicities. This early data demonstrates the potential for a new generation of CAR-T therapies with improved safety and in vivo production. The company also reported encouraging first-in-human results for LB2102, targeting DLL3 in small-cell lung cancer and large-cell neuroendocrine carcinoma. At higher doses, the therapy achieved a 28.6% ORR and a 78.6% disease control rate (DCR), showing durable responses in heavily pretreated patients. Profitability achieved as operating metrics show substantial improvement. For the first time, Legend posted net income: $33.2 million (Q2 2026), reversing a $125.4 million net loss in the same period last year. Adjusted net income (removing non-cash/exchange effects) reached $63.1 million, up from $10.1 million a year prior. The turnaround reflects higher gross profits from CARVYKTI(R), milestone payments, and improved operating leverage. | Metric | Q2 2026 ($M) | Q2 2025 ($M) | YOY Change ($M) | | Net Income (Loss) | 33.2 | (125.4) | 158.6 | | Adjusted Net Income | 63.1 | 10.1 | 53.0 | | Operating Income (Loss) | 57.7 | (21.9) | 79.6 | | Total Revenue | 387.5 | 255.1 | 132.4 | The bottom-line resurgence was accompanied by a robust balance sheet: $965 million in cash and time deposits as of June 30, 2026 - thanks in part to a successful $212 million public offering of American Depositary Shares. The company estimates this financial runway extends beyond 2026, cushioning research, expansion, and future launches. Research spend reflects clinical advances, while cost controls improve leverage. Research and development expenses declined slightly to $96.0 million, as dosing phases of key trials concluded, while commercial and distribution costs climbed with expanded CARVYKTI(R) access and revenue. Administrative expenses remained stable year-over-year, reflecting tight operational control despite expanding global operations. Durable Growth across hematology and oncology portfolio. New CARTITUDE program results continue to support durable efficacy and a consistent safety profile for CARVYKTI(R) in multiple myeloma, including sustained progression-free and overall survival benefits and low rates of severe adverse events. Legend's expanding clinical and commercial footprint across a variety of blood cancers and solid tumors speaks to a maturing, diversified pipeline with real-world momentum. Key takeaway: positioned for long-term value as profitability arrives. Legend Biotech's surge to quarterly profitability, growing CAR-T portfolio, and strengthened cash position confirm the company's transition from rapid innovator to sustainable market leader. Investors and industry watchers may want to focus on upcoming clinical readouts from LB2501, rollout progress for CARVYKTI(R), and whether Legend can deliver multi-quarter profitability - a milestone not just for the firm, but for the cell therapy sector itself. Contact Information: If you have feedback or concerns about the content, please feel free to reach out to Market Chameleon via email at [email protected]. About the Publisher - Marketchameleon.com: Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. Market Chameleon leverage extensive data, models, and analytics to provide valuable insights into these markets. Its primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards. NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com. The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information. Disclosure: This article was generated with the assistance of AI

Legend Biotech

Senior Manager Network Finance & Strategy - Finance

About the job

About the company

Get referred to Legend Biotech

Simplify's Take

What believers are saying

What critics are saying

What makes Legend Biotech unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth